CJC-1295 Near Cénac — What Researchers Need to Know
For anyone in Cénac trying to locate CJC-1295, the first thing to know is that this compound is available only through an online research supply market. What this means for Cénac researchers is that physical proximity is irrelevant compared to your ability to assess COA data — and those evaluation tools are available to every researcher. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. The sections below cover what Cénac researchers need to know about sourcing, verifying, and handling CJC-1295 for legitimate research applications.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Cénac researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source CJC-1295 — Vendor Guide
The first step for any Cénac researcher sourcing CJC-1295 is locating suppliers that experienced researchers actively recommend — search results alone are too heavily influenced by marketing spend. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are within acceptable research limits. Warning signs in CJC-1295 vendor evaluation: prices far under typical market pricing, no information about manufacturing source, no community presence, and COAs that lack endotoxin data. The powdered lyophilised form of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Cénac
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the risk characterisation for this compound is based on research literature rather than clinical trials. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg in 2mL gives a 2.5mg/mL solution — or 25mcg per insulin syringe unit. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger severe inflammatory responses at very low concentrations, and no cost saving makes omitting this acceptable. The research literature on CJC-1295 should be reviewed carefully before planning any study — study methodologies, dosing, and endpoints vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
